These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29189366)

  • 1. Role of Urine Drug Testing in the Current Opioid Epidemic.
    Mahajan G
    Anesth Analg; 2017 Dec; 125(6):2094-2104. PubMed ID: 29189366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
    Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
    Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients.
    Manchikanti L; Malla Y; Wargo BW; Fellows B
    Pain Physician; 2011; 14(2):175-87. PubMed ID: 21412372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoassay in healthcare testing applications.
    DePriest AZ; Black DL; Robert TA
    J Opioid Manag; 2015; 11(1):13-25. PubMed ID: 25750161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urine and oral fluid drug testing in support of pain management.
    Kwong TC; Magnani B; Moore C
    Crit Rev Clin Lab Sci; 2017 Sep; 54(6):433-445. PubMed ID: 28990451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of the accuracy of benzodiazepine testing in chronic pain patients utilizing immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing.
    Manchikanti L; Malla Y; Wargo BW; Fellows B
    Pain Physician; 2011; 14(3):259-70. PubMed ID: 21587329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urine drug screening: a valuable office procedure.
    Standridge JB; Adams SM; Zotos AP
    Am Fam Physician; 2010 Mar; 81(5):635-40. PubMed ID: 20187600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of urine drug testing for patients on opioid therapy.
    Pergolizzi J; Pappagallo M; Stauffer J; Gharibo C; Fortner N; De Jesus MN; Brennan MJ; Richmond C; Hussey D;
    Pain Pract; 2010; 10(6):497-507. PubMed ID: 20412503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicians' perspective on the use of immunoassay versus definitive laboratory quantitation methodologies for medication monitoring.
    McCarberg BH; Kirsh KL; Passik SD
    J Pain Palliat Care Pharmacother; 2014 Sep; 28(3):255-8. PubMed ID: 25102041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower Cutoffs for LC-MS/MS Urine Drug Testing Indicates Better Patient Compliance.
    Krock K; Pesce A; Ritz D; Thomas R; Cua A; Rogers R; Lipnick P; Kilbourn K
    Pain Physician; 2017 Nov; 20(7):E1107-E1113. PubMed ID: 29149155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Family physicians' proficiency in urine drug test interpretation.
    Reisfield GM; Webb FJ; Bertholf RL; Sloan PA; Wilson GR
    J Opioid Manag; 2007; 3(6):333-7. PubMed ID: 18290585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management.
    McCarberg BH
    Postgrad Med; 2011 Nov; 123(6):124-31. PubMed ID: 22104461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory-Generated Urine Toxicology Interpretations: A Mixed Methods Study.
    Chua IS; Ransohoff JR; Ehrlich O; Katznelson E; Virk ZM; Demetriou CA; Petrides AK; Orav EJ; Schiff GD; Melanson SEF
    Pain Physician; 2021 Mar; 24(2):E191-E201. PubMed ID: 33740356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of an opiate immunoassay for detecting hydrocodone and hydromorphone in urine from a clinical population: analysis of subthreshold results.
    Bertholf RL; Johannsen LM; Reisfield GM
    J Anal Toxicol; 2015; 39(1):24-8. PubMed ID: 25288720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urine drug testing in chronic pain.
    Christo PJ; Manchikanti L; Ruan X; Bottros M; Hansen H; Solanki DR; Jordan AE; Colson J
    Pain Physician; 2011; 14(2):123-43. PubMed ID: 21412368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of oral fluid in compliance monitoring of opioid medications.
    Conermann T; Gosalia AR; Kabazie AJ; Moore C; Miller K; Fetsch M; Irvan D
    Pain Physician; 2014; 17(1):63-70. PubMed ID: 24452646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gatifloxacin interference with opiate urine drug screen.
    Straley CM; Cecil EJ; Herriman MP
    Pharmacotherapy; 2006 Mar; 26(3):435-9. PubMed ID: 16503726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid urine drug screens: diphenhydramine and methadone cross-reactivity.
    Rogers SC; Pruitt CW; Crouch DJ; Caravati EM
    Pediatr Emerg Care; 2010 Sep; 26(9):665-6. PubMed ID: 20838187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine Drug Tests: Ordering and Interpreting Results.
    Kale N
    Am Fam Physician; 2019 Jan; 99(1):33-39. PubMed ID: 30600984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Can a Urine Drug Screening Immunoassay Really Tell Us?
    Nelson ZJ; Stellpflug SJ; Engebretsen KM
    J Pharm Pract; 2016 Oct; 29(5):516-26. PubMed ID: 25917168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.